IP Library Granted Patent US 7,378,391
Granted Patent B2
US 7,378,391 · App. 11/232,360 · Granted May 27, 2008

Cyclosporin alkyne analogues and their pharmaceutical uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,391
App. No.
11/232,360
Granted
May 27, 2008
Kind
B2
Abstract

The compounds of the present invention are represented by the chemical structure found in Formula I: or a pharmaceutically acceptable salt thereof, with X, R 0 , R 1 , and R 2 defined herein.

Claims (38)

1. A compound of Formula I:

wherein:

X is OH or OAc;

R 0 is H, CH 2 OH, or CH 2 OR 3 ;

R 1 is hydrogen, deuterium, or methyl;

R 2 is selected from the group consisting of:

hydrogen;

halogen;

C 1 -C 6 saturated or unsaturated, straight or branched carbon chain;

C 1 -C 6 saturated or unsaturated, straight or branched carbon chain containing a substitution or substitutions selected from the group consisting of deuterium, halogen, nitrogen, sulfur, and silicon;

C 1 -C 6 saturated or unsaturated, straight or branched carbon chain containing a function group or function groups selected from the group consisting of alcohol, ether, aldehyde, ketone, carboxylic acid, ester, and amide;

C 1 -C 6 saturated or unsaturated, straight or branched carbon chain containing a function group of oxime or hydrazone;

C 1 -C 6 saturated or unsaturated, straight or branched carbon chain containing an aryl or a heteroaryl group;

C 3 -C 6 substituted and unsubstituted cycloalkyl;

substituted and unsubstituted aryl; and

substituted and unsubstituted heteroaryl; and

R 3 is selected from the group consisting of:

alkanoyl,

alkenoyl,

alkynoyl,

aryloyl,

arylalkanoyl,

alkylaminocarbonyl,

arylaminocarbonyl,

arylalkylaminocarbonyl,

alkyloxycarbonyl,

aryloxycarbonyl, and

arylalkyloxycarbonyl,

wherein the compound is a cis geometric isomer, a trans geometric isomer, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein X is OH or OAc, R 0 is H, CH 2 OH, or CH 2 OAc, and R 1 is H or D.

3. The compound according to claim 2 , wherein R 2 is H.

4. The compound according to claim 2 , wherein R 2 is selected from the group consisting of CH 3 , CD 3 , CH 2 CH 3 , and CH 2 CH 2 CH 3 .

5. The compound according to claim 2 , wherein R 2 is selected from the group consisting of CH═CH 2 , CH═CHCH 3 , C≡CH, and —C≡C—CH 3 .

6. The compound according to claim 2 , wherein R 2 is selected from the group consisting of F, Cl, Br, and I.

7. The compound according to claim 2 , wherein R 2 is cyclopropyl.

8. The compound according to claim 2 , wherein R 2 is selected from the group consisting of CH 2 OH, CH(OH)CH 3 , CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CHO, and C(═O)CH 3 .

9. The compound according to claim 2 , wherein R 2 is selected from the group consisting of CH═N—OCH 3 , CH═N—OCH 2 CH 3 , CH═N—NHCH 3 , and CH═N—N(CH 3 ) 2 .

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1 .

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI RENESSELAER, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 028078/0227 →
TERMINATION Recorded Apr 19, 2012
From: BANK OF AMERICA, N.A.
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.; AMRI RENESSELAER, INC.
Reel/Frame 028072/0335 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2011
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI RENSSELAER, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026397/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2008
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 021998/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2005
From: MOLINO, BRUCE F.; YANG, ZHICAI
To: AMR TECHNOLOGY, INC.
Reel/Frame 017237/0712 →